pentobarbital will lower the extent or impact of lumefantrine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration with sturdy CYP3A4 inducers may lead to reduced serum concentrations and loss of antimalarial efficacypentobarbital will decrease the level or result of imatinib by affecting hepatic/intestinal en